Abstract: Alzheimer disease (AD) and dementia with Lewy bodies (DLB) are common etiologies of dementia with overlapping clinical features. Our objective was to determine which extrapyramidal signs (EPSs) are most helpful in identifying DLB. We analyzed data from the National Alzheimer's Coordinating Center, including demographics, Unified Parkinson's Disease Rating Scale (UPDRS) scores, Mini-Mental State Examination (MMSE) scores, and clinical diagnosis. The subjects were divided into 3 groups: AD, DLB, or Lewy body variant (LBV). The UPDRS motor scores were totaled and analyzed within and across the MMSE strata using regression techniques. Further, we divided UPDRS subscores into 9 EPSs, dichotomized as either present or absent. Logistic regression analysis was used to compare each of the EPS in the AD and Lewy body (DLB + LBV) groups. DLB subjects (n = 130) were more likely to be male individuals, younger, and have higher MMSE scores (P < 0.001) compared with that in AD (n = 1826) or LBV (n = 105) subjects. Differences were found for total UPDRS score and number of EPSs (P < 0.001), after controlling for age, sex, and MMSE. Logistic regression models demonstrated that masked facies best differentiated AD from Lewy body (odds ratio = 6.5, P < 0.001, 95% confidence interval, 3.8-11.1). If these findings are neuropathologically validated, then the presence of specific EPS may help clinicians better differentiate AD and DLB.
A lzheimer disease (AD) and dementia with Lewy bodies (DLB) are common etiologies of dementia with overlapping features. Consensus criteria for DLB, which include cognitive fluctuations, visual hallucinations, and spontaneous parkinsonism, were validated in a British geropsychiatry cohort followed to autopsy, 1,2 with sensitivity and specificity of 83% and 95%, respectively. 2 Similar studies from dementia cohorts in the United States demonstrated much lower sensitivities (31% to 32%), although specificity remained high. 3, 4 Differentiating DLB from AD is important, as there are important therapeutic and prognostic implications to the DLB diagnosis. 1, [5] [6] [7] [8] [9] To that end, this study focuses on one of the 3 consensus criteria, spontaneous parkinsonism. The presence of cognitive fluctuations can be difficult to assess with high interrater reliability. 10 However, some centers have developed and validated methods that have improved the reliability of the assessment of fluctuations in DLB. 11, 12 Visual hallucinations have a lower prevalence in dementia-based clinics 13 compared with that in geropsychiatry-based clinics. 2 Parkinsonian signs can occur in both DLB and AD, particularly in the later stages. 14 Therefore, describing the profile of motor parkinsonism [eg, the severity of extrapyramidal signs (EPSs) and the specific EPS most commonly present] in DLB and AD by dementia stage may be helpful to clinicians in differentiating these disorders. The National Alzheimer's Coordinating Center (NACC) database includes a large, well-characterized dementia cohort with standardized assessments of parkinsonism. Using this database, we examined the relationship between dementia severity [as measured by the Mini-Mental State Examination (MMSE) 15 ] and EPS in individuals with AD and DLB. Further, we identified key EPS that, when present, suggests Lewy body (LB) disease.
METHODS
Cross-sectional data from the NACC were acquired for subjects with a primary or secondary etiological diagnosis of AD and/or DLB. The data were collected from 31 federally funded AD centers between 2005 and 2009. A full description of the Uniform Data Set has been previously published. 16 All centers entering data into the NACC database had Institutional Review Board approval to gather data from human subjects. Written informed consent was obtained from all participants or their surrogate decision makers.
Participants
Subjects were included if: (1) they were 65 years old or above; (2) they had a clinical diagnosis of mild cognitive impairment 17 or dementia; (3) they had an etiological diagnosis of probable AD 18 and/or DLB 1 ; (4) they had Unified Parkinson's Disease Rating Scale (UPDRS) 19 data; and (5) they were not taking antipsychotic or other antidopaminergic medications. UPDRS data included only the motor subscale. Subjects were excluded if they carried a clinical diagnosis of Parkinson disease, parkinsonian-plus syndromes (eg, progressive supranuclear palsy and multiple-system atrophy), normal pressure hydrocephalus, stroke, traumatic brain injury, medication-induced or medical illness-related cognitive impairment, cognitive impairment attributed to psychiatric illness (other than depression), or substance abuse.
Variables
Data requested from NACC included demographics, item-specific subscores on the UPDRS motor subscale, 19 Folstein MMSE scores, 15 estimated age of onset of cognitive decline, and etiological diagnoses. Subjects were divided into 3 groups on the basis of their clinical phenotypic diagnosis. The AD group carried a solitary primary diagnosis of probable AD based on the National Institute of Neurological and Communicative Disorders and Stroke/ Alzheimer's Disease and Related Disorders Association criteria. 18 The DLB group consists of those with a solitary, primary diagnosis of DLB based on published consensus criteria. 1 The "Lewy body variant of AD" (LBV) group includes those with dual diagnoses of AD and DLB, with the DLB diagnosis serving either primary or secondary.
Measures
Primary outcome measures included the UPDRS motor score and the number of EPSs present for an individual. Each center contributing data to the NACC had clinicians that were trained in a standardized manner, using video training provided by the Parkinson's Study Group, to score the motor items on the UPDRS. The UPDRS motor score was defined as the sum of 27 subitems rated from the neurological examination; any individual missing >10 subitems had a missing total score and were excluded from the analysis. All 27 subitems scored in the UPDRS motor subscale were then grouped into 9 EPSs: speech/hypophonia, masked facies, resting tremor, action/postural tremor, rigidity, bradykinesia, impaired chair rise, impaired posture/gait, and postural instability. Speech/hypophonia included the single-item grading speech volume and quality. Masked facies included the single-item grading facial expression. Resting tremor included the 5 subitems grading tremor at rest in the face/lips/chin and 4 extremities. Action/postural tremor included intention tremor in both upper extremities. Rigidity included presence and degree of rigidity in the neck and 4 extremities. Bradykinesia included 9 subitems: bilateral finger tapping, hand movements, rapid alternating movements of the hands, leg agility, and body bradykinesia. Impaired chair rise included the single measure of arising from a chair. Impaired posture/gait combined the items posture and gait. Postural instability included the single item of postural stability. Each of the EPS was graded as absent (score of 0 or 1 of 4) or present (score of 2 to 4, inclusive). A score of 1 indicated very mild parkinsonism that could be considered normal for age 19 ; for that reason, a score of 1 did not indicate the presence of significant parkinsonism for the main analyses of this study. The total number of signs present was then determined for each subject. However, for 2 of the UPDRS items, resting tremor and the gait component of impaired posture/gait, the score of 1 might be considered abnormal regardless of age (eg, resting tremor "slight and infrequently present") and suggestive of significant parkinsonism. Therefore, the analyses for predicting an LB phenotype were repeated secondarily in all the subjects using this lower cutoff for resting tremor and the gait component of impaired posture/ gait. Primary variables of interest were diagnostic group and MMSE. Total MMSE scores were stratified into the following categories for analysis: 0 to 10, 11 to 15, 16 to 20, 21 to 25, and 26 to 30.
Data Analyses
Linear regression models were used to assess differences between diagnostic groups in UPDRS total scores, whereas Poisson regression models were used to assess differences between groups in the number of EPSs present. The total UPDRS score was square rooted before analysis to meet the assumptions of the model. All models were adjusted for age and sex. Assumptions of the models were checked numerically and graphically and were met by the data. Secondary analyses compared the prevalence of each EPS across the diagnostic groups using w 2 tests and the association of EPS with LB phenotype (combined LBV and DLB groups) using logistic regression models adjusted for age, education, sex, and MMSE. Odds ratios (OR) and confidence intervals were also computed. Models were first fit individually for each EPS. A forward stepwise logistic regression model was then built to assess the independent associations of the 9 EPSs with an LB phenotype (DLB or LBV). This model was adjusted for age, education, sex, and MMSE. A joint model including those EPSs found to be significantly associated with LB phenotype in the univariate models was also created to compare with the results of the stepwise regression model. A further analysis considered UPDRS total score as a predictor of LB phenotype in a logistic regression model adjusted for age, education, sex, and MMSE. All analyses were conducted using SAS, version 9.1, and P-values < 0.05 was considered statistically significant.
RESULTS

Sample Characteristics
There were a total of 3429 subjects who met the inclusion criteria. However, we excluded 1368 subjects who either lacked a significant amount of specific UPDRS data (n = 1274) or had excluded clinical diagnoses (n = 94) as detailed in the methods section. Therefore, the total number of subjects included in the analyses was 2061 with 1826 subjects in the AD group, 130 subjects in the DLB group, and 105 subjects in the LBV group. Table 1 describes the study sample. The DLB group was younger, had a higher MMSE, and a higher percentage of males compared with the AD and LBV groups (P < 0.05, corrected for multiple comparisons). This group also had a higher percentage of whites compared with the AD group (P < 0.05, corrected for multiple comparisons). The groups did not differ on the level of education. The DLB group had a shorter disease duration compared with the AD group (P < 0.05, corrected for multiple comparisons). The DLB and LBV groups had higher total UPDRS scores and a higher number of EPSs present compared with the AD group.
Stratification by MMSE
Boxplots of the total UPDRS scores by the MMSE strata within each group illustrate a general trend of increasing UPDRS with a decreasing MMSE (Fig. 1) . In the AD group, the median UPDRS in the highest MMSE stratum (26 to 30) was 5, whereas the median UPDRS in the lowest MMSE stratum (0 to 10) was 11. In the DLB group, the median UPDRS at the highest MMSE (26 to 30) was 15 compared with the median UPDRS at the lowest MMSE stratum (0 to 10) of 39.5. The LBV group had a median UPDRS score of 11 at the highest MMSE stratum (26 to 30) and a median UPDRS of 24 at the lowest MMSE stratum (0 to 10). It is also interesting to note that the AD group had more outliers than did the DLB or LBV groups. In models adjusted for age and sex using the square root of the UPDRS as the outcome, decreasing MMSE remained associated with increasing UPDRS within each group (P < 0.001 for each group). As expected, the 3 groups differed in their total UPDRS scores (P < 0.001), after adjusting for age, sex, and MMSE, with DLB having the highest scores, followed by LBV and then AD. The total UPDRS for the LBV group with the highest MMSE stratum (26 to 30) was similar to the UPDRS in the AD group with the lowest MMSE stratum (0 to 10) (P = 0.9). In contrast, the total UPDRS for the DLB group in the highest MMSE stratum (26 to 30) was significantly higher (P = 0.001) compared with the total UPDRS for the AD group in the lowest MMSE stratum (0 to 10). The results did not change after adjusting for disease duration.
Barplots showing the mean and SD of the total number of EPSs (range, 0 to 9) by MMSE strata within each group also illustrate a general trend of increasing number of EPSs with a decreasing MMSE (Fig. 2) . As expected, the 3 groups differed in their total number of EPSs (P < 0.001), after adjusting for age, sex, and MMSE, with DLB having the highest number of EPSs, followed by LBV and then AD. Within each MMSE stratum, there was a similar gradient of number of EPSs, with DLB having the highest number, followed by LBV and AD. As with the analysis by total motor UPDRS score, the results did not change after adjusting for disease duration. Table 2 gives the prevalence of each EPS by group. For all 9 EPSs, the prevalences were highest in the DLB and LBV groups, as compared with the AD group. For 7 of the 9 EPSs, the LBV group showed prevalences intermediate to the DLB and AD groups (all EPSs except action/postural tremor and impaired chair rise). Further analyses assessed that how each EPS was associated with a diagnosis of an LB disease (DLB or LBV). Table 2 also gives the ORs of having an LB diagnosis in relation to the presence or absence of an individual EPS from models adjusted for age, education, and MMSE. As expected, each specific EPS was associated with significantly increased odds of having an LB diagnosis. The OR for masked facies (OR = 18.6, P < 0.001, see tables for confidence intervals) and hypophonic speech (OR = 14.1, P < 0.001) were particularly high. Adjusted ORs remain similar for resting tremor and impaired posture/gait if the lower cutoffs (scoresZ1 = abnormal) are used ( Table 2 footnote). In the stepwise regression model (Table 3) , each of the EPS remained in the model, except for impaired chair rise and postural instability. Masked facies had the highest OR in the stepwise model (OR = 6.5, P < 0.001), whereas action/postural tremor had the lowest significant OR (OR = 1.9, P = 0.01). The joint model showed very similar ORs (not shown). The overall prediction accuracy of the stepwise regression model was 83.1%. When this model was repeated without the demographic variables or an MMSE score, accuracy dropped to 71.4%. The results were similar after adjusting for disease duration. When the total UPDRS score was entered into the model instead of the specific EPS (with the demographic variables and MMSE), the results were very similar with an overall prediction accuracy of 83.6%. The results of the stepwise regression model with alternate cutoffs for resting tremor and impaired posture/gait also remain similar with an overall accuracy of 84.8% (Supplementary Table 1 , Supplemental Digital Content 1, http:// links.lww.com/WAD/A38). Masked facies still had the highest OR (OR = 5.0, P < 0.001); resting tremor had the lowest (OR = 1.8, P = 0.01).
Analyses by Individual EPS
DISCUSSION
The presence of motor parkinsonism, as measured by the UPDRS, is not specific to any single neurodegenerative disorder; however, the severity of motor parkinsonism and specific EPS may indicate a higher likelihood of a clinical DLB diagnosis. In this study, patients with DLB had the most severe parkinsonism and number of EPS, in comparison with those with LBV and AD. They were also generally younger, were more often male, and had slightly higher MMSE scores compared with those having AD. Of the 3 groups studied, AD subjects had the lowest UPDRS scores and the fewest discrete signs of motor parkinsonism. However, AD subjects had some degree of measurable parkinsonism, which worsened with the cognitive severity of the disease. Those subjects with a late-stage AD [MMSE (0 to 10)] had a similar degree of parkinsonism to those with early-stage LBV [MMSE (26 to 30)], but had significantly less parkinsonism compared with those subjects with earlystage DLB [MMSE (26 to 30) ]. This finding, therefore, might assist the clinician with the diagnosis of DLB, particularly early in the course of the disease.
After describing the degree and number of EPS, our next goal was to identify specific EPS that might help the clinician differentiate AD and LB disease in the clinical setting. Logistic regression models consistently demonstrate that all 9 EPSs differentiate DLB from AD, regardless of age, sex, education, or MMSE. Furthermore, 7 of 9 EPSs were each independently associated with an LB disease, in descending order: masked facies, rigidity, resting tremor, impaired posture/gait, speech/hypophonia, bradykinesia, and action/postural tremor. The final forward stepwise model did not include impaired chair rise or postural instability after accounting for the other 7 EPSs. These 2 signs may be less specific for DLB, as other etiologies common in the geriatric population may also produce these signs, for example, arthropathy of the knees and/or lumbar spine, coexisting cerebrovascular disease, vestibular dysfunction, or peripheral neuropathy with sensory ataxia. These findings were similar to those of a principal component analysis performed by Ballard et al, 20 which demonstrate, in a different population (N = 42 DLB, 30 AD), that rest tremor, action tremor, bradykinesia, facial expression, and rigidity subscales of the UPDRS were helpful in differentiating DLB from AD. Another study by Galasko et al, 21 also showed that masked facies, rigidity, parkinsonian gait, and bradykinesia discriminated between pathology-verified AD and LB disease in a dementia cohort. Our model was based on a much larger sample and included independent associations of MMSE, sex, and age, such that male sex, higher MMSE scores, and younger age were associated with a diagnosis of LB disease. It should be noted that including demographic variables and dementia severity (MMSE) to the model markedly improved discrimination between the groups, beyond that achieved by considering EPS alone. The DLB group had the highest presence of EPSs and the most severe motor parkinsonism overall, despite having shorter estimated disease duration.
There are several limitations of the study. The model assumes that the individual EPSs are independent, although we recognize that they likely are not truly independent. One aspect of this issue is that 2 parkinsonian signs (eg, masked facies and bradykinesia) may cooccur because of the same underlying pathophysiology. Further, the clinical examiner may be influenced by the diagnostic impression or the presence/absence of another sign in determining whether an individual EPS is present. There is some circular logic to the use of parkinsonism in the diagnostic criteria defining the groups studied, then studying the degree of parkinsonism in those groups. As a result, interpreting results using the total UPDRS score is significantly limited. One remedy for this limitation would be the use of objective quantitative measures for parkinsonian signs such as rigidity, 22 tremor, 23 and bradykinesia. 24 These measures deserve further study and development in dementia cohorts. Another limitation of using the total UPDRS motor score is that the UPDRS was developed for measuring symptom severity in Parkinson disease, not as a diagnostic tool in dementia patients. Some academic dementia clinics have shown both utility and good interrater reliability [25] [26] [27] for the UPDRS motor subscale and similar scales in dementia cohorts; however, there are no published interrater reliability studies for the UPDRS as it is used in the NACC database.
Another study limitation is that the cohort studied is a clinical referral population, not a community-based or population-based cohort, limiting the generalizability of the study results. The use of the term LBV remains controversial, and further research into this entity is needed. Our use of the term LBV is meant to capture those subjects who meet criteria for both AD and DLB and have increased likelihood to carry both pathologies. Most cases of DLB are mixed (> 84%), with relatively few cases of pure DLB without AD pathology. [28] [29] [30] The degree of overlapping AD pathology coexistent with LB pathology may mask core symptoms of an LB disease. 28 In the LBV cases in this study, both pathologies may be present and contribute to the clinical picture, such that the subject meets criteria for both AD and DLB. There is, however, a weakness in the DLB critieria, 1 which excludes the presence of other coexisting illnesses, such as AD, which may contribute to the clinical phenotype. If the DLB criteria are strictly interpreted, these mixed cases, which would otherwise meet criteria for DLB, would be classified solely as AD. This reflects the ongoing challenge of accurately identifying mixed pathologies antemortem. The utility of clinically differentiating LBV from pure DLB is not proven, but these overlap cases may have more severe cholinergic deficits. [31] [32] [33] Lastly, this study has not yet been validated by neuropathology in this cohort; future neuropathologic studies are planned once larger samples are available. Previous reports from other Alzheimer disease centers in the United States have found low sensitivity of the consensus DLB criteria in pathologically confirmed DLB cases. 3, 4, 10, 13 Higher sensitivity of the criteria to LB disease has been reported by the Newcastle group, 2 which used a geropsychiatry cohort, in addition to having a tertiary DLB referral center.
The strengths of this study include sample size, statistical power, statistical methods, and the use of the NACC database. NACC obtains data from nationwide tertiaryreferral centers that use widely used and validated clinical measures, such as the UPDRS and diagnostic criteria. The UPDRS data allowed for identification of a profile of motor parkinsonism and demographics associated with LB disease. The very large sample size and stratification by MMSE, a commonly used clinical tool that approximates dementia stage and severity, makes this study a unique addition to the literature. Independent replication and validation of these models and results may allow the more refined use of EPSs to improve diagnostic accuracy in the future.
Differentiating AD from DLB remains a clinical challenge. The differentiation of these disorders is important. Currently, the major treatment difference between DLB and AD is to avoid typical neuroleptic agents and other phenothiazines. 1 Increased sensitivity to the newer antipsychotic drugs may also be seen in DLB. 34 Once specific therapies emerge to treat the a-synucleinopathies, accurate early detection of DLB will become much more important. In this sample, the severity of parkinsonism, in addition to MMSE and demographic data, can help differentiate DLB from AD. The group differences, such as those found in this study, are not always useful at the individual level. The sensitivity and specificity of these EPSs, as compared with the neuropathologic diagnostic criteria for DLB, 1 needs to be determined before we can be confident of their clinical utility. If verified by future autopsy studies, however, the presence of specific signs of parkinsonism, such as masked facies and hypophonic speech, may help clinicians more efficiently diagnose DLB in the clinical setting.
